COMPANY
FDA-approved therapeutic company
Profile checked Oct 10, 2026
Timeline
- FDA FDA CBER noteworthy supplement: ASCENIV (immune globulin intravenous, human-slra) — BLA125590/190, Apr 30, 2026. Applicant at approval: ADMA Biologics. source ↗
- Debt Debt: $30M (not counted as a raise), announced Dec 20, 2024. Source: SEC filing. source ↗
Funding
Debt: $30.0M. Last 2 years.
- Debt: $30M (not counted as a raise), announced Dec 20, 2024. Source: SEC filing. source ↗
FDA records (last 2 years)
- FDA CBER noteworthy supplement: ASCENIV (immune globulin intravenous, human-slra) — BLA125590/190, Apr 30, 2026. Applicant at approval: ADMA Biologics. source ↗
Connect
See your connections at ADMA Biologics on LinkedIn (search by name, results not checked)LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-12
